Biphosphonates and parathyroid hormone analogs for improving bone quality in spinal fusion: State of evidence

Kivanc Atesok,1,2 Martina Stippler,2 Brendan M. Striano,3 Grace Xiong,3 Matthew Lindsey,2 Ely sia Cappellucci,2 Alexandra Psilos,1 Sven Richter,2 Michael J. Heffernan,1 Steven Theiss,4 Efstathios Papavassiliou2
1Children’s Hospital New Orleans/LSU Health Science Center, New Orleans, LA; 2Harvard Medical School, Beth Israel Deaconess Medical Center, Department of Neurosurgery; 3Harvard Combined Orthopaedic Residency Program, Boston, MA; 4University of Alabama at Birmingham, Department of Orthopaedic Surgery, Birmingham, AL, USA

Abstract

Spinal fusion is among the most commonly performed surgical procedures for elderly patients with spinal disorders – including degenerative disc disease with spondylolisthesis, deformities, and trauma. With the large increase in the aging population and the prevalence of osteoporosis, the number of elderly osteoporotic patients needing spinal fusion has risen dramatically. Due to reduced bone quality, postoperative complications such as implant failures, fractures, post-junctional kyphosis, and pseudarthrosis are more commonly seen after spinal fusion in osteoporotic patients. Therefore, pharmacologic treatment strategies to improve bone quality are commonly pursued in osteoporotic cases before conducting spinal fusions. The two most commonly used pharmacotherapeutics are bisphosphonates and parathyroid hormone (PTH) analogs. Evidence indicates that using bisphosphonates and PTH analogs, alone or in combination, in osteoporotic patients undergoing spinal fusion, decreases complication rates and improves clinical outcomes. Further studies are needed to develop guidelines for the administration of bisphosphonates and PTH analogs in osteoporotic spinal fusion patients in terms of treatment duration, potential benefits of sequential use, and the selection of either therapeutic agents based on patient characteristics.

Introduction

Spinal fusion is one of the most commonly performed procedures for treating conditions of the spine, with a reported increase of 113% in the number of procedures between 1998 and 2011 in the United States.1,2 In the same period, the average age of patients undergoing spinal fusion increased from 49 years to just under 56 years, and re-fusion rates rose by 171%.3 It is reasonable to expect a continuing increase in the average age of patients undergoing spinal fusion based on unprecedented rates of population aging.4 Alongside the exponential growth of the aging population, osteopenia and osteoporosis have also become increasingly common conditions. As a result, the number of elderly osteoporotic patients needing instrumented spinal fusion has increased dramatically.4

Spinal instrumentation and fusion in elderly osteoporotic patients with diminished bone density and quality can be a significant challenge for spine surgeons. Despite advances in hardware manufacturing and fixation techniques, adverse outcomes such as proximal junctional kyphosis (PJK), pseudarthrosis, instrumentation failure, graft subsidence, and compression fractures of the adjacent cranial vertebral body are frequently seen in osteoporotic patients after instrumented spinal fusion.5,6 In a retrospective analysis of 140 patients who underwent primary posterior thoracolumbar or lumbar spinal fusion, Bjerke et al. demonstrated that osteoporosis related complications such as PJK, pseudarthrosis, and instrumentation failure were significantly higher in patients with osteopenia and osteoporosis than those with normal bone density.4

Tempel et al showed that patients with DEXA T scores under -1.0 (i.e. with osteopenia or osteoporosis; T-score between -1.0 and -2.5, or less than -2.5 respectively) who undergo stand-alone lateral lumbar interbody fusion are at a much higher risk of developing graft subsidence and are at an increased risk of requiring additional surgery.7 Toyone et al8 studied the long-term prevalence of vertebral fractures after lumbar spinal fusion with instrumentation. These authors suggested that “postmenopausal female patients who underwent lumbar spinal instrumentation surgery were susceptible to develop subsequent vertebral fractures within 2 years after surgery.”9

Since the success of spinal fusion can depend on the quality and quantity of bone, effective pharmacologic treatment strategies to improve bone mineral density and facilitate new bone formation must be pursued in elderly osteoporotic patients before spinal fusion. These pharmacotherapeutic strategies can be divided into three main categories based on their mechanism of action: inhibition of bone resorption using bisphosphonates, stimulation of bone formation with parathyroid hormone (PTH) analogs, or combination therapies with simultaneous or sequential use of bisphosphonates and PTH analogs.9,10

Bisphosphonates

Bisphosphonates (BPs) are the standard antiresorptive agents and the most commonly prescribed drugs for the treatment of osteoporosis.11 To better understand the
clinical outcomes of bisphosphonate use, it is important to elucidate the chemistry that underlies their effect on bone physiology.

Chemical structure and mechanism of action

These pharmacotherapeutics are called bisphosphonates because they contain two phosphate groups in their chemical structure. This molecular structure is very similar to that of naturally occurring pyrophosphates thereby inhibits activation of the enzymes that utilize pyrophosphates. Once absorbed into the circulation, bisphosphonates are quickly retained in the skeleton with the highest concentrations found at sites of active bone resorption. A high concentration of BPs at resorption sites interrupts osteoclast function and induces osteoclast apoptosis, which results in decreased resorption and bone loss.

Commonly used BPs and current evidence

There are several bisphosphonates available for the treatment of osteoporosis including, but not limited to alendronate, risedronate, ibandronate, and zoledronic acid. While alendronate, risedronate, and ibandronate are available in oral formulations, zoledronic acid is only available in an intravenously delivered form. Ibandronate also has an intravenous formulation. Once a patient is deemed appropriate for pharmacologic osteoporosis therapy, the treatment is chosen based on multiple different clinical factors, including renal function and tolerance of oral medications. Due to the mechanism of bisphosphonate excretion via the kidney, and the lack of clinical trial data in patients with osteoporosis and severe renal impairment, BPs should not be used in patients with CrCl <30–35 mL/min.

The efficacy of bisphosphonates in reducing the risk of fractures in postmenopausal women has been demonstrated in multiple large scale, randomized controlled trials. The incidence of vertebral fracture has been shown to be reduced with any of the most common bisphosphonates: alendronate, risedronate, ibandronate, or zoledronic acid (Table 1). There is convincing evidence to support the positive impact of BPs on bone quality and outcomes in osteoporotic patients undergoing spinal fusion. In a retrospective comparative study of 64 osteoporotic patients undergoing lumbar spinal fusion, post-operative administration of 5mg of zoledronic acid infusion was shown to increase the speed of fusion. In patients treated with IV zoledronic acid, the fusion rates at three and six months were found to be 90%, compared with 70% and 75% in the control group, respectively (P<0.05). Despite the increased speed of fusion, there was no significant difference between the two groups at 12 months post-operatively. Additionally, there was a significant decrease in vertebral compression fractures in the group treated with zoledronic acid (P<0.05). In another retrospective comparative study, Tu et al. compared 32 osteoporotic patients who underwent lumbar interbody fusion surgery (LIFS) and received 5 mg of zoledronic acid infusions at three days and one year after the surgery, with 32 patients with osteoporosis who underwent LIFS but did not receive zoledronic acid postoperatively. At the two-year follow up, 75% of the patients treated with zoledronic acid achieved fusion, compared with 56% in the control group. Control group patients were noted to have developed significantly more vertebral compression fractures, loosened pedicle screws, and cage subsidence. Chen et al. performed a prospective randomized, placebo controlled, and triple-blind trial including 69 osteoporotic patients treated with either zoledronic acid infusion (5 mg) or placebo (the same volume of saline) after single-level posterior lumbar interbody fusion (PLIF). The zoledronic acid group was associated with significantly higher rates of fusion at three, six, and nine months postoperatively (P<0.05). However, there was no statistically significant difference between the experimental and control groups at the 12-month follow up. No patients in zoledronic acid group developed adjacent vertebral compression fractures, whereas six patients (17 %) in the control group did (P<0.05). Furthermore, the mean Oswestry disability index (ODI) score in the zoledronic acid group was significantly lower compared with the control group at nine months and 12 months after the surgery (P<0.05).

In another prospective randomized controlled study, Nagahama et al. evaluated the effects of postoperative weekly alendronate (35 mg) administration on spinal fusion in patients undergoing single-level PLIF. The alendronate-treated group achieved significantly higher rates of fusion, with 95% fusion at the one-year follow up compared with only 65% in the control group treated daily with 1 µg vitamin D (P=0.025). Additionally, the use of alendronate protected against the subsequent development of vertebral compression fracture: it occurred in 24% of patients in the control group versus 0% in the alendronate treated group (P=0.027). Interestingly, the results of this study showed that bone formation markers in the alendronate group was elevated at one and three months after surgery but decreased below preoperative levels six months postoperatively. However, bone formation markers in the control group remained above the preoperative levels at one, three, six, and 12 months after surgery. Bone resorption markers in the control group were above the preoperative levels at one and three months postoperatively, while the levels were below the preoperative baseline throughout the postoperative period for the alendronate group.

Based on existing evidence, it can be suggested that the use of bisphosphonates in osteoporotic patients promotes lumbar intervertebral fusion and reduces subsequent vertebral compression fractures.

Table 1. Level I studies showing the decrease in vertebral fracture risk with the use of BPs in postmenopausal woman.

| Medication   | Study            | Evidence Level | Follow Up Time | Result                          |
|--------------|------------------|----------------|----------------|---------------------------------|
| Alendronate  | Kushida et al.   | Level I        | 3 years        | Risk Reduction 58% (P < 0.05)    |
|              |                  |                |                | Relative Risk = 0.41, 95% CI (0.18-0.97) |
| Risedronate  | Regnister et al. | Level I        | ≥3 years       | Risk Reduction 49% (P = 0.001)   |
| Ibandronate  | Chesnut et al.   | Level I        | ≥3 years       | *Risk Reduction 62% (P = 0.001)  |
| Zoledronic Acid | Black et al.    | Level I        | 3 years        | Risk Reduction 70% (P < 0.001)   |
|              |                  |                |                | Relative Risk = 0.30, 95% CI (0.24-0.38) |

*The results of the study from Chesnut et al.2 showed 62% risk reduction for daily regimen and 59% risk reduction for intermittent regimen. Abbreviations: CI (confidence interval).
Chemical structure and mechanism of action

PTH is an 84-amino-acid polypeptide that plays a central role in the maintenance of calcium homeostasis by directly increasing calcium reabsorption in kidneys and indirectly enhancing calcium absorption in intestines by stimulating renal calcitriol.12 Although persistently high PTH levels, as occur in primary hyperparathyroidism, result in the predominance of osteoclast-mediated bone resorption and consequent net bone loss, intermittent administration of synthetic PTH analogs leads to a predominance of osteoblast-mediated bone formation.31 PTH promotes osteoblast growth and decreases osteoblast apoptosis. Activation of the PTH receptor in osteoblasts induces signaling pathways essential for osteoblast proliferation and differentiation. Through the same signaling pathway, sclerostin (a bone formation inhibitor) production is also reduced (Figure 1).34

Commonly used PTH analogs and current evidence

Teriparatide and Abaloparatide are the two recombinant PTH analogs approved by the Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women. It is assumed that the biological activity of intact PTH resides in the N-terminal of its amino-acid sequence. Teriparatide has a sequence identical to that of the 34 N-terminal amino acids (the biologically active region) of the 84-amino-acid human parathyroid hormone. It is administered as a subcutaneous injection into the thigh or abdominal wall and the recommended dosage is 20 µg once a day. Teriparatide is extensively absorbed after subcutaneous injection with a bioavailability of 95%. Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver followed by excretion via the kidneys. Since the safety and efficacy of teriparatide have not been evaluated beyond two years of treatment, use of this drug for more than two years is not recommended.35 Animal research showed an unequivocal increase in bone tumor incidence only after an extended duration of treatment (20 or 24 months) at the highest dose level of teriparatide (30 µg/kg).36 Fortunately, seven-year results from an ongoing 15-year post-marketing surveillance study have not detected a pattern indicative of a causal relationship between teriparatide treatment and adult osteosarcoma in humans.37

Neer et al studied the effects of teriparatide treatment in a prospective randomized placebo controlled trial including 1637 postmenopausal women with prior vertebral fractures.38 Their results showed that treatment of postmenopausal osteoporosis with teriparatide decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated. The respective relative risks of new vertebral fractures in the 20-µg and 40-µg teriparatide treatment groups, as compared with the placebo group, were 0.35 and 0.31 respectively (95% confidence intervals, 0.22 to 0.55 and 0.19 to 0.50).39 Although the two dose regimens had similar effects on the risk of fracture, the 40-µg dose increased bone mineral density more than the 20-µg dose and was more likely to cause side effects.

Literature includes high-level evidence supporting the use of teriparatide treatment to enhance osseous union in osteoporotic patients undergoing instrumented spinal fusion.39-41 In a prospective randomized study, Ebata et al. assessed the role of once-weekly teriparatide administration on patient outcomes following posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF).39 Seventy-five osteoporotic patients were randomly selected to receive either weekly teriparatide administered subcutaneously from week one, for six months postoperatively (the teriparatide arm), or no teriparatide (the control arm). Six months postoperatively, complete fusion occurred in 69.0% of the patients in the teriparatide arm and in 35.1% of the patients in the control arm (P=0.013).

Inoue et al studied the efficacy of preoperative teriparatide in affecting insertional torque of pedicle screws during fusion surgery in postmenopausal women with osteoporosis.40 Twenty-nine patients who had thoracic and/or lumbar spine fusion were divided into two groups based on whether they were treated with teriparatide (N=13) or not (N=16) before the surgery. In the teriparatide-treated group, patients received preoperative teriparatide therapy as either a daily (20 mcg/day, N=7) or a weekly (56.5 mcg/week, N=6) injection for a mean of 61.4 days and a minimum of 31 days. During surgery, the insertional torque was measured in 212 screws inserted from T-7 to L-5 and compared between the two groups. The mean insertional torque value in the teriparatide group was significantly higher than in the control group (P<0.01). There was no significant difference between the daily and weekly teriparatide groups with respect to mean insertional torque value. The authors suggested that teriparatide injections beginning at least one month prior to surgery can be effective in increasing the insertional torque of pedicle screws during surgery in patients with postmenopausal osteoporosis.40

Abaloparatide is also a 34-amino-acid analog of the amino-terminal (1-34) fragment of human PTH. Abaloparatide is con-
considered to be more selective in stimulating bone formation without increasing bone resorption. The minimal effects of abaloparatide on bone resorption may relate in part to lesser increases in the pro-resorptive cytokine RANKL (receptor activator of nuclear factor kappa B ligand) compared with the effect of teriparatide. The recommended dosage of abaloparatide is 80 mcg subcutaneously once daily. Similar to teriparatide, cumulative use of abaloparatide for more than 2 years during a patient’s lifetime is not recommended. The metabolism of abaloparatide is consistent with non-specific proteolytic degradation into smaller peptide fragments, followed by elimination by renal clearance.

In a double-blind randomized clinical trial including 2463 postmenopausal women with osteoporosis (Abaloparatide Comparator Trial in Vertebral Endpoints—ACTIVE), Miller et al demonstrated that the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months. New morphometric vertebral fractures occurred in 0.58% (N=4) of the participants in the abaloparatide group and in 4.22% (N=30) of those in the placebo group (risk difference [RD] versus placebo, −3.64 [95% CI, −5.42 to −2.10]; relative risk, 0.14 [95% CI, 0.05 to 0.39]; P<0.001). The abaloparatide-treated group demonstrated significant increases in bone mineral density (BMD) from baseline at the total hip, femoral neck, and lumbar spine (P<0.001).

Miller et al further studied the results from 2463 postmenopausal women with osteoporosis in the ACTIVE to compare the response to treatment with daily injections of abaloparatide 80 mcg with matching placebo or open-label daily injections of teriparatide 20 mcg for 18 months. The proportions of patients experiencing BMD gains from a baseline of >0%, >3%, and >6% at the total hip, femoral neck, and lumbar spine at six, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups. Responders were defined prospectively as patients experiencing BMD gains at all three anatomic sites. At months six, 12, and 18, there were significantly more >3% BMD responders in the abaloparatide group compared with the placebo and teriparatide groups: month six, 19.1% versus 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% versus 1.5% and 19.8%; month 18, 44.5% versus 1.9% and 32.0% (P<0.001 for all comparisons of abaloparatide to placebo and to teriparatide). The authors concluded that, “In postmenopausal women with osteoporosis, a significantly greater proportion of patients treated with abaloparatide experienced increases in BMD than did those treated with placebo or teriparatide.”

Although available evidence indicates that abaloparatide has the potential to increase bone formation and improve BMD, no clinical studies to date have reported on the effects of abaloparatide treatment on bony union in osteoporotic patients undergoing instrumented spinal fusion.

### Bisphosphonates versus PTH Analogs

After the introduction of PTH analogs, researchers performed studies comparing bisphosphonates with PTH analogs to develop better treatment algorithms for enhancing osseous union after spinal fusion in osteoporotic patients. Table 2 summarizes the results from some of the studies that compared the use of teriparatide versus bisphosphonates in osteoporotic women undergoing instrumented spinal fusion. Overall, there is supportive evidence that teriparatide use alone is associated with higher osseous fusion rates compared with the use of bisphosphonates alone.

### Combined Use of Bisphosphonates and PTH Analogs

To obtain superior effects on the skeleton, combined use of an antiresorptive bisphosphonate with a bone-forming PTH analog was put forward as an appealing hypothesis.

Although evidence suggests potential advantages of using simultaneous combination therapies on hip BMD over monotherapy alone, the effect of combination therapies on spine BMD, osteoporotic fracture incidence, and postoperative spinal fusion needs to be further studied (Table 3).

### Sequential Use of Bisphosphonates and PTH Analogs

PTH analogs are not recommended to be used for more than two years, due to concerns over neoplasms raised by animal stud-

| Study | Evidence Level | Follow Up Time | Study Design | Results |
|-------|----------------|----------------|--------------|---------|
| Cho et al., 47 | Level II | 24 months | PLIF patients treated postoperatively with alendronate (N=24, 91.37 mg/week continuous) versus teriparatide (N=23, 20 mcg/day SC 3-month cycles alternating with 3-month periods of 91.37 mg/week PO alendronate) | Shorter average interbody fusion duration in teriparatide group (P=0.006) |
| Ohtori et al., 48 | Level III | 12 months | Lumbar spinal fusion patients treated 2 months pre- and 10 months postoperatively with risedronate (N=20, 2.5 mg/day) versus teriparatide (N=20, 20 mcg/day SC). Control group (N=22, received no treatment). | Lower incidence of pedicle screw loosening in teriparatide group versus risedronate or control groups (P<0.05) |
| Seki et al., 49 | Level III | 24 months | Patients treated for 3 months before and 21 months after spinal deformity surgery with bisphosphonates (N=25, risedronate 2.5 mg/day in 5 patients and alendronate 5 mg/day in 20 patients) versus teriparatide (N=53, 20 mcg/day SC). | Higher total fusion rate and lower adjacent vertebral fracture rate in teriparatide group than in bisphosphonate group (P=0.0002 and P=0.003, respectively) |
gained after discontinuation of bone forming therapy.

Promptly could limit the loss in BMD and continue for a minimum of five months after surgery. It is advisable to switch to an additional two years of treatment. However, there may be potential benefits in sequential use of PTH analogs and bisphosphonates. We suggest that, unless there is any contraindication, every elderly osteoporotic patient should start PTH analogs at least four to six months after surgery. It is advisable to switch to an antiresorptive bisphosphonate after discontinuation of PTH analogs to preserve the gain in BMD. Decisions on the extension of PTH analog treatment at six months after operation, the type of bisphosphonate to be initiated, and duration of treatment, must be taken on a case-by-case basis.

### Summary and Authors’ Suggestions

Osteoporosis presents a unique challenge for spine surgeons as it relates to achieving osseous union following instrumented spinal fusion. Antiresorptive bisphosphonates and bone forming PTH analogs are two commonly used pharmacotherapeutics to minimize the risk of postoperative complications due to reduced bone quality in elderly osteoporotic patients. The use of bisphosphonates or PTH analogs alone has shown to improve bone quality in osteoporosis. There is evidence that using PTH analogs alone is associated with higher osseous-union rates than the use of bisphosphonates alone after instrumented spinal fusion. Although simultaneously inhibiting osteoclasts and stimulating osteoblasts may sound sensible, concurrent use of bisphosphonates and PTH analogs has not been proven to be more efficacious for treatment of osteoporosis than using either therapy alone. However, there may be potential benefits in sequential use of PTH analogs and bisphosphonates. We suggest that, unless there is any contraindication, every elderly osteoporotic patient should start PTH analogs at least four to six months after surgery. It is advisable to switch to an antiresorptive bisphosphonate after discontinuation of PTH analogs to preserve the gain in BMD. Decisions on the extension of PTH analog treatment at six months after operation, the type of bisphosphonate to be initiated, and duration of treatment, must be taken on a case-by-case basis.

### References

1. Rajae SS, Bae HW, Kanim LE, Delamarter RB. Spinal fusion in the United States: analysis of trends from 1998 to 2008. Spine (Phila Pa 1976). 2012;37:67-76.

2. Andersson G, Watkins-Castillo SI. The Burden of Musculoskeletal Diseases in the United States. https://www.boneandjointsurden.org/2014-report/iiel/spinal-fusion (Accessed on May 1st, 2019)

3. He W, Goodkind D, Kowal P. U.S. Census Bureau, International Population Reports, P95/16-1, An Aging World: 2015. U.S. Government Publishing Office, Washington, DC, 2016. https://www.census.gov/content/dam/Census/library/publications/2016/demo/p95-16-1.pdf (Accessed on May 1, 2019)

4. Bjerke BT, Zarrabian M, Aleem IS et al. Incidence of Osteoporosis-Related Complications Following Posterior Lumbar Fusion. Global Spine J 2018;8:563-569.

5. Formby PM, Kang DG, Helgeson MD, Wagner SC. Clinical and Radiographic Outcomes of Transforaminal Lumbar Interbody Fusion in Patients with

### Table 3. Studies reporting the results of combination bisphosphonate and PTH analog therapy for postmenopausal osteoporosis.

| Study            | Evidence Level | Follow Up Time | Study Design                                                                 | Results                                                                 |
|------------------|----------------|----------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Cosman et al.53  | Level II       | 12 months      | Zoledronic acid IV single injection 5 mg plus teriparatide SC 20 µg/day (N=137), versus zoledronic acid alone (N=137), or teriparatide alone (N=138). | Higher hip BMD increase in combination group versus teriparatide alone (P=0.02). Higher lumbar spinal BMD increase in combination group versus zoledronic acid alone (P<0.001). Lower fracture incidence in combination group versus zoledronic acid alone (P=0.04). |
| Black et al.52   | Level I        | 12 months      | Alendronate 10 mg/day plus PTH (1-84) 100 µg/day (N=59), versus alendronate alone (N=60), or PTH (1-84) alone (N=119). | No significant difference in lumbar spinal BMD increase between the groups. Higher hip BMD increase in combination group versus PTH group (P<0.02). No evidence of synergy between PTH and alendronate. Concurrent use of alendronate may reduce the anabolic effects of PTH. |
| Deal et al.53    | Level I        | 6 months       | Teriparatide 20 µg/day SC plus PO raloxifene 60 mg/day (N=69), versus teriparatide plus placebo (N=68). | Higher hip BMD increase in combination group (P=0.04). No significant difference between groups in lumbar spinal BMD increase. |
| Finkelstein et al.54 | Level II     | 30 months      | Teriparatide 40 µg/day SC plus alendronate 10 mg/day PO (N=31), versus alendronate alone (N=31) or teriparatide alone (N=31). | Higher lumbar spinal and femoral neck BMD increase with teriparatide alone than with alendronate alone (P<0.001) or with combination (P<0.045 and P<0.001, respectively). Alendronate reduced the ability of teriparatide to increase BMD. |
Osteoporosis. Global Spine J 2016;6:660-664.
6. Kim JS, Phan K, Cheung ZB et al. Surgical, Radiographic, and Patient-Related Risk Factors for Proximal Jugal Instability: A Meta-Analysis. Global Spine J 2019;9:32-40.
7. Tempel ZJ, Gandhoke GS, Okonkwo DO, Kanter AS. Impaired bone mineral density as a predictor of graft subsidence following minimally invasive transspoas lateral lumbar interbody fusion. Eur Spine J 2015;24 Suppl 3:414-9.
8. Toyone T, Ozawa T, Kamikawa K et al. Subsequent vertebral fractures following spinal fusion surgery for degenerative lumbar disease: a mean ten-year follow-up. Spine (Phila Pa 1976). 2010;35:1915-8.
9. Park SB, Chung CK. Strategies of spinal fusion on osteoporotic spine. J Korean Neurosurg Soc 2011;49:317-22.
10. Cusano NE, Bilezikian JP. Combination anabolic and antisresorptive therapy for osteoporosis. Endocrinol Metab Clin North Am. 2012;41:643-54.
11. Appelman-Dijkstra NM, Papapoulos SE. Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. Drugs 2015;75:1049-58.
12. Teschemaker A, Lee E, Xue Z, Wutoh AK. Osteoporosis pharmacotherapy and counseling services in US ambulatory care clinics: opportunities for multidisciplinary interventions. Am J Geriatr Pharmacother. 2008;6:240-8.
13. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010;363:2027-35.
14. Rodan G, Reszka A, Golub E et al. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin. 2004, 20: p. 1291-300.
15. Ding N, Liu C, Yao L et al. Alendronate induces osteoclast precursor apoptosis via peroxisomal dysfunction mediated ER stress. J Cell Physiol. 2018. 233: p. 7415-7423.
16. Bergstrom JD, Bostedor RG, Masarachia PJ et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000. 373: p. 231-41.
17. Miller PD, Jamal SA, Evenepoel P et al. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 2013;28:2049-59.
18. Kushida K, Shiraki M, Nakamura T et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 2004;22:462-8.
19. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
20. Soen S, Umemura T, Ando T et al. Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice. J Bone Miner Metab 2017;35:419-427.
21. Chesnut CH 3rd, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
22. Ito M, Tobinai M, Yoshida S et al. Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study. J Bone Miner Metab 2017;35:58-64.
23. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1808-22.
24. Chen F, Dai Z, Kang Y et al. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion. Osteoporos Int 2016;27:1469-1476.
25. Ding Q, Chen J, Fan J et al. Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients. Eur Spine J 2017;26:2969-2977.
26. Nagahama K, Kanayama M, Togawa D et al. Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. J Neurosurg Spine 2011;14:500-507.
27. Tu CW, Huang KF, Hsu HT et al. Zoledronic acid infusion for lumbar interbody fusion in osteoporosis. J Surg Res 2014;192:112-116.
28. Park YS, Kim HS, Baek SW et al. The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion. Clin Orthop Surg 2013;5:292-297.
29. Liu WB, Zhao WT, Shen P, Zhang FJ. The effects of bisphosphonates on osteoporotic patients after lumbar fusion: a meta-analysis. Drug Des Devel Ther. 2018;12:2233-2240.
30. Hodsman A, Papaioannou A, Cranney A. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ. 2006 Jul 4;175:48.
31. Canalis E. Management of endocrine disease: Novel anabolic treatments for osteoporosis. Eur J Endocrinol 2018;178:R33-R44.
32. Hodsman AB, Bauer DC, Dempster DW et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
33. Augustine M, Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep. 2013;11:400-6.
34. Kraenzlin ME, Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol. 2011;7:647-56.
35. Forteo - FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021318s015lbl.pdf (Accessed on January 31, 2020)
36. Vahle JL, Long GG, Sandusky G et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32:426-38.
37. Andrews EB, Gilsenan AW, Midkiff K et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012;27:2429-37.
38. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1343-41.
39. Ebata S, Takahashi J, Hasegawa T et al. Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: A multicenter, prospective randomized study. J Bone Joint Surg Am 2017;99:365-372.
40. Inoue G, Ueno M, Nakazawa T et al. Teriparatide increases the insertion torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine 2014;21:425-31.
41. Ohtori S, Inoue G, Orita S et al. Parathyroid hormone and parathyroid hormone-related protein analogs for osteoporosis: a narrative review. Int J Mol Sci 2019;20:1533.
42. Hodsman AB, Bauer DC, Dempster DW et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
43. Augustin M, Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep. 2013;11:400-6.
44. Kanetoz ME, Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol. 2011;7:647-56.
45. Forteo - FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021318s015lbl.pdf (Accessed on January 31, 2020)
46. Vahle JL, Long GG, Sandusky G et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32:426-38.
47. Andrews EB, Gilsenan AW, Midkiff K et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012;27:2429-37.
48. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1343-41.
49. Ebata S, Takahashi J, Hasegawa T et al. Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: A multicenter, prospective randomized study. J Bone Joint Surg Am 2017;99:365-372.
50. Inoue G, Ueno M, Nakazawa T et al. Teriparatide increases the insertion torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine 2014;21:425-31.
42. Chandler H, Lanske B, Varela A et al. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone. 2019;120:148-155.
43. Tymlos - FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf (Accessed on February 2, 2020)
44. Miller PD, Hattersley G, Riis BJ et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA 2016;316:722-733.
45. Miller PD, Hattersley G, Lau E et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone. 2019;120:137-140.
46. Buerba RA, Sharma A, Ziino C et al. Bisphosphonate and Teriparatide Use inThoracolumbar Spinal Fusion: A Systematic Review and Meta-analysis of Comparative Studies. Spine (Phila Pa 1976). 2018;43:E1014-E1023.
47. Cho PG, Ji GY, Shin DA et al. An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J 2017;26:691-697.
48. Ohtori S, Inoue G, Orita S et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013;38:E487-92.
49. Seki S, Hirano N, Kawaguchi Y et al. Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis. Eur Spine J 2017;26:2121-2127.
50. Cosman F. Combination therapy for osteoporosis: a reappraisal. Bonekey Rep. 2014;3:518.
51. Cosman F, Eriksen EF, Recknor C et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011;26:503-11.
52. Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
53. Deal C, Omizo M, Schwartz EN et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20:1905-11.
54. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010;95:1838-45.
55. Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone 2017;98:54-58.